The Food and Drug Administration has approved a new flu vaccine made with the same mRNA technology that was used for the COVID-19 shots.

The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA ...

Drug stock Moderna (MRNA) is pulling back to a historically bullish trendline and has plenty of contrarian signals flashing ...

Moderna (MRNA) valuation in focus: weak Q2, cash outlook, FDA win for mFLUSIVA, pipeline risks and sales hurdles.

The shot, mFlusiva, was given a traditional approval for adults aged 50 to 64, ​and an accelerated approval for ​those 65 ...

The FDA has approved mFlusiva, the first mRNA-based influenza vaccine, for adults aged 50 years and older, with accelerated approval for those 65 and older.

The decision caps a seven-month process that included a rare refusal to consider the shot.

The approval of the vaccine, called mFLUSIVA, which is manufactured by Moderna, follows a series of blows to mRNA research ...

Moderna received FDA approval for its new mRNA-based flu shot for older adults after months of regulatory questioning.

The vaccine could give Moderna a foothold in seasonal flu and strengthen the case for mRNA shots against fast-changing ...

The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...